BioVie Targets Neuroinflammation and Insulin Resistance in Parkinson’s Treatment Approach

Why It Matters

A therapy that tackles neuroinflammation and insulin resistance could shift Parkinson’s care from symptom management to disease modification, attracting significant investor interest and expanding the biotech pipeline.

Key Takeaways

• BioVie links neuroinflammation and insulin resistance to Parkinson’s pathology.
• Lead candidate Beziterim reduces inflammation and reverses insulin resistance in trials.
• Combination with Levodopa improved motor control versus Levodopa alone.
• New trial tests Beziterim monotherapy in early‑stage Parkinson’s patients.
• Topline data expected by end of June, could reshape treatment paradigm.

Summary

BioVie’s CEO Cuong Do explained the company’s hypothesis that Parkinson’s disease is driven not only by dopamine loss but also by neuroinflammation‑induced insulin resistance. The firm is developing Beziterim, a molecule designed to clear the “rust” on cellular insulin receptors, thereby restoring glucose uptake and neuronal energy.

In an earlier trial, Beziterim added to standard Levodopa therapy produced statistically significant gains in motor function compared with Levodopa alone. The drug also lowered biomarkers of neuroinflammation and reversed insulin‑resistance metrics, providing a human proof‑of‑concept for the dual‑target strategy.

The ongoing study enrolls 60 newly diagnosed Parkinson’s patients, randomizing half to Beziterim monotherapy and half to placebo. Researchers will assess both motor outcomes and non‑motor symptoms such as sleep disturbance, anxiety, and depression, aiming to demonstrate broader disease‑modifying benefits.

If topline results, due by the end of June, confirm these effects, Beziterim could become the first therapy to address the metabolic component of Parkinson’s, opening a new market segment and prompting a reevaluation of treatment algorithms.

Original Description

BioVie CEO Cuong Do joined Steve Darling from Proactive to discuss the company’s novel approach to treating Parkinson’s disease, focusing on neuroinflammation and insulin resistance as key drivers of the condition.

Do challenged the traditional view of Parkinson’s as solely a dopamine-related disorder, explaining that inflammation in the brain may play a more fundamental role. He noted that insulin resistance can impair the ability of brain cells to access glucose, stating, “If you have inflammation, the inflammation acts like rust on that lock… and therefore the door stays closed and glucose cannot get in.” This lack of energy in neurons may contribute significantly to disease progression.

BioVie’s lead drug candidate, Bezisterim, is designed to target these underlying mechanisms. According to Do, clinical trials have shown that patients receiving the therapy experienced reductions in neuroinflammation along with improvements in insulin sensitivity. Earlier studies combining Bezisterim with Levodopa also demonstrated enhanced muscle control compared to standard treatment alone.

The company is now advancing a new clinical trial evaluating Bezisterim as a standalone therapy in early-stage Parkinson’s patients. The study is designed to assess both motor and non-motor symptoms, including sleep, anxiety, and depression.

With enrollment now complete, BioVie is targeting a topline data readout before the end of June, marking an important near-term catalyst for the program.

proactiveinvestors #biovieince #nasdaq #bivi #NeurodegenerativeDiseases #parkinsonsdisease #BrainHealth #BioVie #CognitionImprovement #Neuroinflammation #SocialImpact #ElderlyCare #Neuroscience #HealthCrisis #DementiaSupport #BrainScience #GlobalHealth #InsulinResistance #Biotech #DrugDevelopment #ClinicalTrials #Bezisterim #CNSResearch #Neuroscience #HealthcareInnovation #MedicalResearch #Biopharma #Neurodegeneration #ToplineData